Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZBIO
stocks logo

ZBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast ZBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBIO is 43.00 USD with a low forecast of 37.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ZBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBIO is 43.00 USD with a low forecast of 37.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 38.110
sliders
Low
37.00
Averages
43.00
High
46.00
Current: 38.110
sliders
Low
37.00
Averages
43.00
High
46.00
Morgan Stanley
Judah Frommer
Overweight
maintain
$34 -> $37
2025-11-13
Reason
Morgan Stanley
Judah Frommer
Price Target
$34 -> $37
2025-11-13
maintain
Overweight
Reason
Morgan Stanley analyst Judah Frommer raised the firm's price target on Zenas BioPharma (ZBIO) to $37 from $34 and keeps an Overweight rating on the shares after the company reported its Q3 update. The "highly anticipated" Phase 3 INDIGO results in IgG4-RD expected around year-end "should offer another opportunity for positive share inflection" if obexelimab data are competitive with Amgen's (AMGN) Uplizna, the analyst tells investors.
H.C. Wainwright
H.C. Wainwright
Buy
upgrade
$30 -> $44
2025-10-28
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $44
2025-10-28
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Zenas BioPharma to $44 from $30 and keeps a Buy rating on the shares. The firm says obexelimab achieved the primary endpoint of 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions versus placebo in the Phase 2 MoonStone trial.
Citi
Buy
upgrade
$27 -> $46
2025-10-28
Reason
Citi
Price Target
$27 -> $46
2025-10-28
upgrade
Buy
Reason
Citi raised the firm's price target on Zenas BioPharma to $46 from $27 and keeps a Buy rating on the shares. The company reported "strong" Phase 2 MoonStone results for obexelimab in relapsing multiple sclerosis that outperformed expectations, the analyst tells investors in a research note. Citi believes the bull case for obexelima is playing out.
Morgan Stanley
Overweight
maintain
$31 -> $34
2025-10-28
Reason
Morgan Stanley
Price Target
$31 -> $34
2025-10-28
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Zenas BioPharma to $34 from $31 and keeps an Overweight rating on the shares after the company reported 12-week data from the Ph2 MoonStone trial of obexelimab in relapsing MS. 24-week data due in Q1 of 2026 will inform further development, the analyst noted.
Morgan Stanley
Overweight
to
Buy
downgrade
$35 -> $31
2025-07-03
Reason
Morgan Stanley
Price Target
$35 -> $31
2025-07-03
downgrade
Overweight
to
Buy
Reason
Morgan Stanley assumed coverage of Zenas BioPharma with an Overweight rating with a price target of $31, down from $35. Upcoming readouts in 4Q25 the first half of 2026 could demonstrate the potential of inhibiting B cells in autoimmune conditions while building out the pipeline-in-a-product potential of obexelima, the analyst tells investors in a research note.
Wedbush
Martin Fan
Buy
Initiates
$35
2025-03-20
Reason
Wedbush
Martin Fan
Price Target
$35
2025-03-20
Initiates
Buy
Reason
Wedbush initiated coverage of Zenas BioPharma with an Outperform rating and $35 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zenas Biopharma Inc (ZBIO.O) is -10.97, compared to its 5-year average forward P/E of -3.87. For a more detailed relative valuation and DCF analysis to assess Zenas Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.87
Current PE
-10.97
Overvalued PE
-1.25
Undervalued PE
-6.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.73
Undervalued EV/EBITDA
-4.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
33.64
Current PS
0.00
Overvalued PS
76.06
Undervalued PS
-8.78
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 7114.31% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 7114.31% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ZBIO News & Events

Events Timeline

(ET)
2025-11-12
07:17:26
Zenas BioPharma Announces Q3 Earnings Per Share of $1.22, Exceeding Consensus Estimate of 85 Cents
select
2025-10-27 (ET)
2025-10-27
07:13:18
Zenas BioPharma announces obexelimab achieved primary goal in Phase 2 MoonStone study
select
2025-10-08 (ET)
2025-10-08
05:10:59
Zenas BioPharma to Offer 6.3 Million Shares at $19.00 in Private Placement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-11Newsfilter
Zenas BioPharma Set to Showcase at Upcoming Healthcare Investment Conferences

  • Company Overview: Zenas BioPharma, a clinical-stage biopharmaceutical company, focuses on developing transformative therapies for autoimmune diseases, with a strategy centered on acquiring and developing promising product candidates.

  • Upcoming Presentations: Zenas will present at the Jefferies Global Healthcare Conference on November 18, 2025, and the 8th Annual Evercore Healthcare Conference on December 3, 2025, with live webcasts available on their website.

  • Lead Product Candidates: The company is advancing two late-stage molecules: obexelimab, a bifunctional monoclonal antibody targeting B cell activity, and orelabrutinib, a selective oral BTK inhibitor aimed at treating CNS-related autoimmune conditions.

  • Additional Programs: Zenas is also developing earlier-stage programs, including a preclinical oral IL-17AA/AF inhibitor and a brain-penetrant TYK2 inhibitor, both of which are positioned as potentially best-in-class therapies.

[object Object]
Preview
5.0
10-29MarketWatch
Seven Tech Stocks Experience Significant Insider Selling Despite Price Increases

  • Insider Sentiment: Corporate insiders are exhibiting a high level of bearish sentiment, the most pessimistic since 1974.

  • Sell/Buy Ratio: The recent sell/buy ratio for all exchanges reached 17.32, indicating a strong bearish outlook, as values above 6 are considered bearish.

[object Object]
Preview
6.0
10-28Benzinga
Morgan Stanley Keeps Overweight Rating on Zenas BioPharma and Increases Price Target to $34

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro equips traders with tools and information designed to improve their chances of success in the markets.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zenas Biopharma Inc (ZBIO) stock price today?

The current price of ZBIO is 38.11 USD — it has increased 3.93 % in the last trading day.

arrow icon

What is Zenas Biopharma Inc (ZBIO)'s business?

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

arrow icon

What is the price predicton of ZBIO Stock?

Wall Street analysts forecast ZBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBIO is 43.00 USD with a low forecast of 37.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zenas Biopharma Inc (ZBIO)'s revenue for the last quarter?

Zenas Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Zenas Biopharma Inc (ZBIO)'s earnings per share (EPS) for the last quarter?

Zenas Biopharma Inc. EPS for the last quarter amounts to -1.22 USD, increased 32.61 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zenas Biopharma Inc (ZBIO)'s fundamentals?

The market is revising Downward the revenue expectations for Zenas BioPharma, Inc. (ZBIO) for FY2025, with the revenue forecasts being adjusted by -78.95% over the past three months. During the same period, the stock price has changed by 85.81%.
arrow icon

How many employees does Zenas Biopharma Inc (ZBIO). have?

Zenas Biopharma Inc (ZBIO) has 130 emplpoyees as of December 05 2025.

arrow icon

What is Zenas Biopharma Inc (ZBIO) market cap?

Today ZBIO has the market capitalization of 2.05B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free